Identification and susceptibility profile of Candida fermentati from a worldwide collection of Candida guilliermondii clinical isolates

Journal of Clinical Microbiology

Volumn 47, Issue 1, 2009, Pages 242-244

  Lockhart, Shawn R ^a,b   Messer, Shawn A ^a   Pfaller, Michael A ^a   Diekema, Daniel J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA FERMENTAI; CANDIDA GUILLERMONDII; CONTROLLED STUDY; DISEASE PREDISPOSITION; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POPULATION DISTRIBUTION; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CROSS INFECTION; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

CANDIDA FERMENTATI; PICHIA GUILLIERMONDII;

EID: 58849102686     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01889-08     Document Type: Article

References (20)

1. Bai, F.-Y. 1996. Separation of Candida fermentati comb. nov. from Candida guilliermondii by DNA base composition and electrophoretic karyotyping. Syst. Appl. Microbiol. 19:178-181.
2. Bishop, J. A., N. Chase, S. S. Magill, C. P. Kurtzman, M. J. Fiandaca, and W. G. Merz. 2008. Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: susceptibility data and documentation of presumed infection. J. Clin. Microbiol. 46:443-146.
3. Borman, A. M., R. Petch, C. J. Linton, M. D. Palmer, P. D. Bridge, and E. M. Johnson. 2008. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J. Clin. Microbiol. 46:933-938.
4. Cuenca-Estrella, M., L. Rodero, G. García-Effrón, and J. L. Rodriguez-Tudela. 2002. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J. Antimicrob. Chemother. 49:981-987.
5. Lan, L., and J. Xu. 2006. Multiple gene genealogical analyses suggest divergence and recent clonal dispersal in the opportunistic human pathogen Candida guilliermondii. Microbiology 152:1539-1549.
6. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2008. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J. Clin. Microbiol. 46:2659-2664.
7. Lockhart, S. R., S. A. Messer, M. A. Pfaller, and D. J. Diekema. 2008. Lodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infections. J. Clin. Microbiol. 46:374-376.
8. Medeiros, E. A., T. J. Lott, A. L. Colombo, P. Godoy, A. P. Coutinho, M. S. Braga, M. Nucci, and M. E. Brandt. 2007. Evidence for a pseudo-outbreak of Candida guilliermondii fungemia in a university hospital in Brazil. J. Clin. Microbiol. 45:942-947.
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth microdilution antifungal susceptibility testing of yeast, 2nd ed. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
10. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kaufman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
11. Pemán, J., M. Bosch, E. Cantón, A. Viudes, I. Jarque, M. Gómez-García, J. M. García-Martínez, and M. Gobernado. 2008. Fungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year period. Diagn. Microbiol. Infect. Dis. 60:109-112.
12. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Ten-dolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
13. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
14. Pfaller, M. A., D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S. C. Chang, D. L. Gibbs, and V. A. Newell. 2006. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J. Clin. Microbiol. 44:3551-3556.
15. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activity of fluconazole and voriconazole determined by broth microdilution, disk diffusion, and Etest methods against 1,586 recent clinical isolates of Candida species: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol. 41:1440-1446.
16. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
17. San Millán, R. M., L. C. Wu, I. F. Salkin, and P. F. Lehmann. 1997. Clinical isolates of Candida guilliermondii include Candida fermentati. Int. J. Syst. Bacteriol. 47:385-393.
18. Tavanti, A., A. D. Davidson, N. A. R. Gow, M. C. J. Maiden, and F. C. Odds. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292.
19. Umamaheswari, K., and T. Menon. 2008. Candida fermentati from HIV patients in Chennai, South India. Int. J. Infect. Dis. 12:e153-e154.
20. Wisplinghoff, H., T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, and M. B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317.